HOME >> BIOLOGY >> NEWS
AAAS denounces anti-evolution laws as hundreds of K-12 teachers convene for 'Front Line' event

ST. LOUIS, MO.--The Board of Directors of the world's largest general scientific organization, the American Association for the Advancement of Science (AAAS), today strongly denounced legislation and policies that would undermine the teaching of evolution and "deprive students of the education they need to be informed and productive citizens in an increasingly technological, global community."

Across the United States, at least 14 pending laws -- including Missouri HB 1266 -- differ in language and strategy, but "all would weaken science education," said AAAS President Gilbert S. Omenn, professor of medicine, genetics and public health at the University of Michigan, Ann Arbor. "The AAAS Board of Directors opposes these attacks on the integrity of science and science education," he added. "They threaten not just the teaching of evolution, but students' understanding of the biological, physical, and geological sciences."

Pending U.S. anti-evolution legislation currently includes: Alabama HB 016/ SB 45, Michigan HB 5251, Michigan HB 5606, Missouri HB 1266, Mississippi SB 2427, Mississippi HB 953, New York A 8036, Oklahoma SB 1959, Oklahoma HB 2107, Oklahoma HCR 1043, South Carolina S 909 and Utah SB 96

Some of these bills would seek to discredit evolution by emphasizing "flaws" in the theory of evolution, or "disagreements" within the scientific community, the AAAS Board noted. Other bills would encourage teachers and students to explore the concept of intelligent design or other non-scientific "alternatives" to evolution, or to "critically analyze" evolution and "the controversy". But, AAAS emphasized, "There is no significant controversy within the scientific community about the validity of evolution."

Moreover, "Evolution is one of the most robust and widely accepted principles of modern science," the AAAS Board concluded, reconfirming its October 18, 2002 statement,
'"/>


19-Feb-2006


Page: 1 2 3 4

Related biology news :

1. New egg freezing technique offers hope to hundreds of women
2. Expedition allows teachers to participate in polar research
3. High school students, teachers join Pitts Gene Team
4. APS awards more than $150,000 in fellowships to middle and high school science teachers
5. From research labs to the schools: Science teachers bring summer science to the classroom
6. Developed/emerging market biotech firms convene at largest-ever meeting with global health focus
7. Research physiologists convene for 120th Annual Meeting
8. Europes leading life science researchers are to convene for the first annual EuroBioForum
9. Environmental toxicology experts to convene at Penn symposium
10. USC and AAAS/Science convene leading innovators to discuss challenges to US preeminence
11. 20th annual convention of US naturopathic physicians convenes Aug. 24, 2005 in Phoenix

Post Your Comments:
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: